TY - JOUR
T1 - Combination Therapies for Obesity
AU - Camilleri, Michael
AU - Acosta, Andres
N1 - Funding Information:
Dr. Camilleri is supported by NIH grant R01-DK67071. The work was supported by Endoscopy and Physiology Core Laboratory, CTSA grant number UL1-TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.
Publisher Copyright:
© Copyright 2018, Mary Ann Liebert, Inc., publishers 2018.
PY - 2018/10
Y1 - 2018/10
N2 - The objective of this review is to examine advances in the development of combination therapies for the treatment of obesity beyond diet or lifestyle interventions. Experimental combination pharmacotherapies include combinations of pramlintide and phentermine as well as amylin and bupropion-naltrexone. Incretin and pancreatic hormones generally inhibit upper gastrointestinal motor functions, and combinations showing efficacy in obesity are coadministration of glucagon-like peptide-1 (GLP-1) with glucagon, a unimolecular dual incretin of PEGylated GLP-1/GIP coagonist, the combination of GLP-1 and PYY3-36, and, in proof of concept studies, combined infusions of GLP-1, peptide YY, and oxyntomodulin. Among bariatric procedures, repeat intragastric balloon (IGB) treatments are more efficacious than IGB plus diet, and endoscopic intervention can enhance the effects of Roux-en-Y gastric bypass when weight regain occurs. A first trial has provided promising results with combination of IGB plus the GLP-1 analog, liraglutide, compared to the balloon alone. Thus, combination therapies for the treatment of obesity hold promise for introduction into clinical practice.
AB - The objective of this review is to examine advances in the development of combination therapies for the treatment of obesity beyond diet or lifestyle interventions. Experimental combination pharmacotherapies include combinations of pramlintide and phentermine as well as amylin and bupropion-naltrexone. Incretin and pancreatic hormones generally inhibit upper gastrointestinal motor functions, and combinations showing efficacy in obesity are coadministration of glucagon-like peptide-1 (GLP-1) with glucagon, a unimolecular dual incretin of PEGylated GLP-1/GIP coagonist, the combination of GLP-1 and PYY3-36, and, in proof of concept studies, combined infusions of GLP-1, peptide YY, and oxyntomodulin. Among bariatric procedures, repeat intragastric balloon (IGB) treatments are more efficacious than IGB plus diet, and endoscopic intervention can enhance the effects of Roux-en-Y gastric bypass when weight regain occurs. A first trial has provided promising results with combination of IGB plus the GLP-1 analog, liraglutide, compared to the balloon alone. Thus, combination therapies for the treatment of obesity hold promise for introduction into clinical practice.
KW - GLP-1
KW - glucagon
KW - obesity
KW - pharmacotherapies
UR - http://www.scopus.com/inward/record.url?scp=85054418668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054418668&partnerID=8YFLogxK
U2 - 10.1089/met.2018.0075
DO - 10.1089/met.2018.0075
M3 - Article
C2 - 29993319
AN - SCOPUS:85054418668
SN - 1540-4196
VL - 16
SP - 390
EP - 394
JO - Metabolic Syndrome and Related Disorders
JF - Metabolic Syndrome and Related Disorders
IS - 8
ER -